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ABSTRACT Recently we reported on the efﬁcacy of pentosan polysulfate (PPS), a
heparan sulfate mimetic, to reduce the recruitment of inﬂammatory inﬁltrates and
protect the cartilage matrix from degradation in Ross River virus (RRV)-infected PPS-
treated mice. Here, we describe both prophylactic and therapeutic treatment with
PG545, a low-molecular-weight heparan sulfate mimetic, for arthritogenic alphaviral
infection. We ﬁrst assessed antiviral activity in vitro through a 50% plaque reduction
assay. Increasing concentrations of PG545 inhibited plaque formation prior to viral
adsorption in viral strains RRV T48, Barmah Forest virus 2193, East/Central/South Afri-
can chikungunya virus (CHIKV), and Asian CHIKV, suggesting a strong antiviral mode
of action. The viral particle-compound dissociation constant was then evaluated
through isothermal titration calorimetry. Furthermore, prophylactic RRV-infected PG545-
treated mice had reduced viral titers in target organs corresponding to lower clinical
scores of limb weakness and immune inﬁltrate recruitment. At peak disease, PG545-
treated RRV-infected mice had lower concentrations of the matrix-degrading enzyme
heparanase in conjunction with a protective effect on tissue morphology, as seen in
the histopathology of skeletal muscle. Enzyme-linked immunosorbent assay quantiﬁ-
cation of cartilage oligomeric matrix protein and cross-linked C-telopeptides of type II
collagen as well as knee histopathology showed increased matrix protein degradation
and cartilage erosion in RRV-infected phosphate-buffered saline-treated mice compared
to their PG545-treated RRV-infected counterparts. Taken together, these ﬁndings suggest
that PG545 has a direct antiviral effect on arthritogenic alphaviral infection and curtails
RRV-induced inﬂammatory disease when administered as a prophylaxis.
KEYWORDS GAGs mimetics, alphaviruses, anti-inﬂammatory, athritogenic, heparan
sulfate mimetics
Ross River virus (RRV) is a clinically relevant mosquito-borne arthritogenic arbovirusfrom the Togaviridae family, Alphavirus genus, together with chikungunya virus
(CHIKV), Sindbis virus (SINV), and Barmah Forest virus (BFV) (1). The typical RRV clinical
presentation is characterized by the sudden onset of fever, maculopapular rash, and
musculoskeletal pain with lethargy in patients with RRV disease (RRVD). Certain patients
(approximately 40 to 60% of sufferers) progress to a persistent debilitative form of a
chronic inﬂammatory arthralgia with agonizing pain (2, 3).
RRVD remains a notiﬁable disease, in addition to being the largest contributor to the
annual disease burden (n  5,000) of arboviral infections in Australia (4, 5). Recently,
rapid globalization has facilitated the spread of CHIKV from the Eastern to the Western
Hemisphere, with outbreaks occurring from 2005 to 2017 (6). Despite the relevance and
importance of these infectious arthritic diseases, there still lies an unmet therapeutic
gap of a targeted treatment given the unsuitability of nonsteroidal anti-inﬂammatory
drugs or steroid treatments for certain patient cohorts.
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Previous studies on CHKV disease (CHIKVD) and RRVD in mice and human subjects
have determined clinical disease to be exacerbated by inﬂammatory immunocytes,
such as monocytes, macrophages, or neutrophils. For example, an initial study on the
synovial exudates of RRVD patients reported the presence of 35% mononuclear inﬁl-
trates in the joint space of these patients (7). Moreover, other studies on CHIKV reported
that treating CHIKV-infected mice with bindarit, a monocyte chemotactic protein 1
(MCP-1; CCL2) inhibitor, reduced the bone loss and muscle degradation seen in
CHIKV-infected mice (8, 9). Recently a study described that in the absence of CCR2
receptors in the mouse model, the usual monocyte-macrophage proﬁle shifts to a
neutrophil-dominated pathogenic response (10).
We recently found the levels of heparanase (HPSE), an endoglycosidase found at
basal homeostatic levels in immune cells such macrophages and neutrophils, to be
upregulated in RRV-infected primary human chondrocytes and primary human skeletal
muscle cells (11). HPSE acts primarily to cleave heparan sulfate (HS) molecules and has
been found to contribute to inﬂammation-driven pathology in a range of human
diseases (for a recent review, see reference 12), such as inﬂammatory bowel disease
(IBD), cancer, and even rheumatoid arthritis (RA) (13–15). A study on RA found that both
active heparanase and the transcript levels of the enzyme were elevated greater than
100-fold in the synovial ﬂuid of patients (14). Furthermore, like the pathology of other
inﬂammatory musculoskeletal disorders, such as osteoarthritis (OA) and RA, where
progressive depletion of proteoglycans occurs in the affected articular cartilage, carti-
lage degradation has also been reported in both RRV- and CHIKV-infected mice (10, 16,
17). Notably, we previously found that at peak RRVD, ankle joints of mice undergo
thinning of articular cartilage with the inclusion of a thickened pannus (16). Our
laboratory recently established that repurposing pentosan polysulfate (PPS), already
used as a disease-modifying drug to treat canines with OA, should also be investigated
to treat human arthritogenic alphaviral diseases (18). We found that PPS treatment of
both CHIKV- and RRV-infected mice resulted in disease amelioration and cartilage
protection. As such, PPS has progressed to a phase 2 clinical trial that is currently
ongoing, targeted to long-term RRV patients (16).
The therapeutic discovery of PPS provided the basis for the current study. We
sought to expand the repertoire of HS mimetics and determine if HS mimetics could be
a class of disease-modifying therapeutics for arthritogenic, alphaviral diseases such as
RRVD. We strategically chose PG545 (19, 20), a drug candidate recently in phase 1
clinical trials in cancer patients (ClinicalTrials registration no. NCT02042781), with an
anti-heparanase and anti-inﬂammatory therapeutic proﬁle. Additionally, recent publi-
cations on PG545 report the compound demonstrates antiviral effects on HS binding
viruses (21–24). Arthritogenic alphaviruses have been reported to initiate entry through
HS binding on host cells (25, 26). In this study, we show that PG545 treatment worked
effectively as a prophylaxis to alphaviral infection in mice and cells. RRV disease
abatement occurred through both the reduction of viral particles as well as a damp-
ened immune response with an overall reduction in tissue damage. We also noticed a
reduced loss of articular cartilage and epiphyseal growth plate that otherwise occurs
with RRV-mediated arthritis. Furthermore, we conﬁrm our previous data, of the up-
regulation of heparanase in RRV-infected human primary cells, by showing upregula-
tion of HPSE in RRVD mice. Overall, we conclude that PG545 is an effective anti-
heparanase prophylactic treatment for arthritogenic alphaviral infections.
RESULTS
PG545 demonstrates efﬁcient dose-dependent plaque inhibition on alphavirus-
infected Vero cells. To test antiviral effects and determine the required compound dose
to achieve a 50% plaque inhibition, various concentrations of PG545 (42.3 M [100
g/ml], 8.46 M [20 g/ml], 1.69 M [4 g/ml], 0.34 M [0.8 g/ml], and 0.068 M
[0.16 g/ml]) were coincubated with viral isolates before viral adsorption. As a control,
we also investigated the plaque inhibition ability of PG545 when used after viral
adsorption to host cell. The results (Fig. 1Ai to Di and Table 1) demonstrate that PG545
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FIG 1 PG545 binds to arthritogenic alphaviruses and inhibits productive infection of Vero cells in a dose-dependent manner at previral adsorption.
(Ai to Di) Fivefold dilutions of PG545 were coincubated with viral strains (RRV T48, chikungunya East/Central/South African virus [CHIKV ESCA],
Asian CHIKV, and BFV2193) and then assayed for overall plaque formation. IC50 dose was determined by normalizing plaques to mock-infected
controls. (Aii to Dii) The corresponding thermodynamic graphs of PG545 binding to virus, where upper panels show raw heat of ligand binding
while lower panels show binding isotherms ﬁtted to the raw data using a single-state binding model. Q, heat.
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reduced the plaque-forming ability of the various athritogenic alphaviral strains effec-
tively prior to viral adsorption, with IC50 (half maximum inhibitory compound concen-
tration) values ranging from 1.94 M (4.57 g/ml) to 0.16 M (0.37 g/ml). However,
when treatment was initiated after viral adsorption, plaque inhibition was poor (Table
1; see also Fig. S1 in the supplemental material).
We next characterized the binding interactions between PG545 and whole virus by
isothermal titration calorimetry (ITC) (Fig. 1Aii to Dii and Table 1), evaluating the
stoichiometry (binding sites) and binding constants (KD; i.e., the thermodynamic bind-
ing constant representing the dissociation/association ratio of compound to virus).
Figure 1Aii to Dii shows thermodynamic parameters of PG545 binding to virus variants.
Overall the KD values ranged from 4.01 (0.42) M to 0.25 (0.12) M, demonstrating
efﬁcient binding afﬁnity of PG545 to the viral proteins. This efﬁcient binding correlates
with the IC50 data, which show the ability of PG545 to inhibit virus to nanomolar ranges.
Prophylactic PG545 treatment reduces the severity of clinical signs and RRV-
induced inﬂammation. To assess PG545 as a treatment strategy for RRV disease, mice
were preloaded with PG545 subcutaneously (s.c.) at 20 mg/kg of body weight and then
infected with RRV or mock infected with phosphate-buffered saline (PBS) alone. Mice
were then treated with a second dose of PG545 at 10 mg/kg within a 10-day time frame
(Fig. 2Ai). This prophylactic treatment regimen resulted in a signiﬁcant reduction of
disease scores at 8 days postinfection (dpi) (P value of 0.05), 9 dpi (P value of 0.01),
and 10 dpi (P value of 0.05) in the RRV-infected PG545-treated group, in addition to
a comparable reduction in RRVD-induced weight loss at 8 (P value of 0.05), 9 (P value
of 0.01), and 10 (P value of 0.001) dpi (Fig. 2Aii and iii). To further evaluate the
reduction in clinical disease, the inﬂammatory response and histopathology of RRV-
infected PBS- and PG545-treated mice were compared. Muscles from RRV-infected PBS-
or PG545-treated mice were harvested at peak disease (10 dpi) for both histology (Fig.
2Bi and ii) and ﬂow cytometry (Fig. 2Ci and ii). Predictably, the control muscle tissues
were only sparsely populated with immune cells, with well-preserved muscle ﬁber
architecture for mock-infected PBS control (mean count of 555.50  67.5), or mock-
infected PG545-treated (mean count of 623.25  42.96) samples (Fig. 2Bii). Supporting
other studies, RRV-infected PBS-treated mice presented with characteristic impairment
of the longitudinal muscular ﬁbrils in addition to marked polymorph nuclear leukocytic
accumulation (mean count of 2,359.25  345.63) (Fig. 2Bii). Notable necrotic ﬁbers
scattered and separated by dense immunocytes were also observed in the RRV-infected
PBS-treated group. In contrast, RRV-infected PG545-treated mice displayed muscle ﬁber
morphology with cross striations and no necrosis. In addition, there were lower
numbers of inﬁltrating immune cells than those for the RRV-infected PBS-treated group
(mean count of 703.25 34.53) (Fig. 2Bii). To characterize the effect of PG545 treatment
on both lymphocytic and myeloid cell populations, the leukocyte subset response
within the muscles was analyzed by ﬂow cytometry. The RRV-infected PBS-treated or
RRV-infected PG545-treated myocytes were stained for Gr-1 CD11b and CD3 cell
surface antigen markers found on granulocytes (neutrophils), monocytes, and T cells. At
TABLE 1 Binding proﬁle between athritogenic alphaviruses and PG545
Virus strain
(laboratory adapted)
IC50 (M)a
KD (M) nbPreadsorption Postadsorption
Asian CHIKV 1.94 (2.69) 8.50 (0.18) 4.01 (0.42) 0.75 (0.45)
ECSA CHIKV 0.51 (0.50) 26.8 (11.05) 0.35 (0.22) 1.47 (0.34)
RRV T48 0.52 (0.36) 15.35 (8.50) 0.34 (0.19) 2.26 (0.91)
BFV 2193 0.16 (0.01) 8.12 (3.76) 0.25 (0.12) 1.10 (0.05)
aIC50 determinations were done on the various virus strains at preadsorption and postadsorption stages
using virus plaque inhibition assays. The binding constant (KD) and the number of binding sites in viral
proteins were calculated using isothermal calorimetry titration, where binding parameters were calculated
thermodynamically. All values in the table are represented as means  SEM from 2 or 3 independent
experiments.
bn, number of active binding sites in viral protein.
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10 dpi, PG545 treatment signiﬁcantly (P value of 0.05) (Fig. 2Cii) reduced the per-
centages of Gr-1/high CD11b/high-expressing inﬂammatory monocytes and Gr-1/mid
CD11b/high-expressing neutrophils in RRV-infected PG545-treated mice (inﬂammatory
monocytes, mean reduction of 2.92% 0.95%; neutrophils, mean reduction of 9.39%
FIG 2 Prophylactic PG545 treatment ameliorates RRVD in mice at peak disease. (Ai) C57BL/6 mice were infected (s.c.) with 104
PFU/50 l RRV or PBS alone on day 0 and received s.c. injections of PG545 or PBS diluents from on day 1 and day 4 after
infection. (Aii and iii) Mice were weighed and scored for disease progression as described in Materials and Methods. (Bi)
Muscles were ﬁxed in 4% PFA and H&E or PTAH stained. (Bii) Total cell inﬁltrates were counted using Image J and then
graphed. (Ci and ii) Enzymatically digested muscle homogenates were stained for neutrophils (Gr1/high CD11b/high) and
inﬂammatory monocytes (Gr1/mid CD11b/high). Each data point represents the means  SEM from 4 to 6 mice and is
representative of 2 or 3 independent experiments. PBS, mock-infected PBS control; PG545, mock infected and PG545 treated;
RRV, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545 treated.
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2.23%) compared to the RRV-infected PBS-treated mice group (inﬂammatory mono-
cytes, mean of 10.47%  1.17%; neutrophils, mean of 20.42%  0.99%). Interestingly,
PG545 treatment did not alter the CD3 lymphocytic T-cell response between the
RRV-infected PG545-treated (mean of 32.94%  3.55%) and RRV-infected PBS-treated
groups (mean of 31.78%  2.11%) (data not shown).
Prophylactic PG545 treatment reduces RRV load in target tissues. To evaluate
the antiviral potency of prophylactic PG545 treatment in vivo, viral titers and viral load
were measured from joints, muscles, and serum of RRV-infected PG545-treated and
RRV-infected PBS-treated mice groups at 1, 3, 5, 7, and 10 dpi. Serum and ankle titers
at 3 dpi showed reduced titers in RRV-infected PG545-treated mice that were statisti-
cally signiﬁcant (Fig. 3Bi [P value of0.05] and ii [P value of0.0001]) compared to the
RRV-infected PBS-treated mice. Whereas other time points showed an overall reduction
in viral titer, no statistical signiﬁcance was noted; however, a generally dampened
kinetic pattern was observed in RRV-infected PG545-treated mice from 7 dpi to 10 dpi
in ankles and 5 dpi to 7 dpi in muscles.
To assess the reduction of viral RNA, quantitative PCR (qPCR) was performed. The
results demonstrated reduction in residual virus load in both muscles and joints of
RRV-infected PG545-treated mice compared to RRV-infected PBS-treated mice at 7 dpi
and 10 dpi, coinciding with disease onset.
Prophylactic PG545 treatment downregulates the expression levels of proin-
ﬂammatory soluble host mediators in target organs of RRV-infected mice. Soluble
inﬂammatory host factors are known to modulate inﬂammatory responses and aid in
the activation or recruitment of various inﬂammatory leukocyte subsets in alphaviral
pathology. Since the inﬁltration of immunocytes was dampened in the RRV-infected
PG545-treated group compared to that of the RRV-infected PBS-treated group, as seen
in ﬂow cytometry and H&E staining, we decided to further assess the expression levels
of host factors which play an important role in both viral infection and inﬂammation.
Cytokine gene expression studies revealed that mRNA levels of proinﬂammatory tumor
necrosis factor alpha (TNF-), interleukin-6 (IL-6), vascular endothelial growth factor A
(VEGF-A), gamma interferon (IFN-), and MCP-1 were all markedly lower in RRV-infected
PG545-treated groups than in RRV-infected PBS-treated groups. Interestingly, while the
mock-infected PG545-treated group showed trends similar to those of the mock-
infected PBS group, PG545 treatment did show a statistically signiﬁcant elevation of
VEGF-A (P value of 0.0001) (Fig. 4) and TNF- (P value of 0.0001) (see Fig. 9) in the
joints compared to levels for the PBS treatment group.
Expression levels of MCP-1 in both muscle and joint was signiﬁcantly (P value of
0.0001) (Fig. 4) lower in the RRV-infected PG545-treated group than in the RRV-
infected PBS-treated group. Reduction in gene expression was also detected for IL-6
(muscle, P value of 0.01; joint, P value of 0.0001), IFN- (muscle, P value of 0.05;
joint, P value of 0.001), and TNF- (muscle, P value of 0.0001) in RRV-infected
PG545-treated groups. Expression levels of TNF- in joints showed a modest elevation
in the RRV-infected PBS-treated group (mean fold increase of 3.94  0.29), with a
consistent trend of lower expression noted in the RRV-infected PG545-treated joint
(mean fold decrease of 3.75  0.25). Interestingly, the overall expression levels of
VEGF-A, in both joint (mean fold increase of 0.76  0.06) and muscles (mean fold
increase of 0.50  0.12), were higher in RRV-infected PG545-infected mice than in
RRV-infected PBS-treated groups (joint, mean fold decrease of 0.67  0.03; muscle,
mean fold decrease of 0.19 0.02), with statistical signiﬁcance of a P value of0.5 (Fig.
4) noted for the muscles. Overall, these ﬁndings were consistent with other previously
published data, which have shown that lowering viremia by antiviral drug treatments
could also reduce the acute inﬂammatory response, as represented by reduction in
proinﬂammatory cytokine levels (27, 28).
Prophylactic PG545 treatment reduces HPSE levels in mice. HPSE, the extracel-
lular matrix (ECM)-degrading enzyme, had higher fold expression in the RRV-infected
PBS-treated joint at a mean of 2.00 0.09 (P value of0.0001) than in the RRV-infected
Supramaniam et al. Antimicrobial Agents and Chemotherapy
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PG545-treated group (mean fold of 1.13  0.08) (Fig. 5ii). As noted in our previous
human primary cell study (11), HPSE was also upregulated in RRV-infected PBS-treated
muscles at a mean fold increase of 3.66  0.23, while PG545 treatment of RRV-infected
mice showed signiﬁcantly (P value of 0.05) reduced HPSE expression at a mean fold
FIG 3 Prophylactic PG545 treatment deters RRV replication and inﬂuences the reduction of viral genomic material at target
tissues. Twenty-one-day-old C57BL/6 RRV-infected mock-treated or RRV-infected PG545-treated mice were infected subcuta-
neously (s.c.) with 104 PFU RRV in the right thorax. At 1, 3, 5, 7, and 10 dpi, serum, muscle, ankles, and knees were harvested.
Muscle and joint tissues were homogenized for plaque assay and/or RNA extracted for viral genomic material analysis. (Ai and
ii) To determine viral load within the musculoskeletal tissues, plasmid copy numbers were extrapolated from RRV T48
standards (n  7) with the qPCR detection limit set at 38 copies of viral RNA transcript per 10 ng template. (Bi to iv) The
amounts of infectious virus in tissues and serum were titrated in Vero cells and expressed as PFU/mg or PFU/ml, with the lower
plaque detection limit set at 50 PFU/ml. Data points are displayed as means  SEM for 4 to 10 mice per treatment group. PFU,
PFU per milliliter. RRV, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545 treated.
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FIG 4 Prophylactic PG545 treatment reduces upregulation of soluble host factors in RRVD mice. Muscles and joints were
homogenized and RNA extracted to analyze soluble host factor expression via qPCR. The y axis is the ﬁnal calibrated transcript
expression graphed as fold shift, and the x axis designates the treatment groups. PBS, mock-infected PBS control; PG545, mock
infected and PG545 treated; RRV, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545 treated. Values are
expressed as mean  SEM mRNA fold changes in expression for 4 or 5 mice in each group.
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decrease of 2.37  0.40 (Fig. 5i). Further, enzyme-linked immunosorbent assay (ELISA)
quantiﬁcation of HPSE protein levels in muscles (Fig. 5iii) conﬁrmed the transcriptional
proﬁle seen in Fig. 5i, with a P value of 0.01 between the infected mock-treated and
infected compound-treated group. This suggests a prominent role of HPSE in exacer-
bating RRVD, as recently reported for RA and other inﬂammatory-mediated pathogen-
eses.
Prophylactic PG545 treatment protects cartilage from damage associated with
RRVD. Recently, RRVD was shown to induce both bone and joint pathology through
the loss of articular cartilage and thinning of epiphyseal growth plates. This is in
addition to the widespread bone loss of the vertebrae and long bones in RRV-infected
mice. It was also reported that PPS, a relevant HS mimetic, is protective against the loss
of proteoglycan matrix in both the articular surfaces and epiphyseal growth plates in
the joints of RRV-infected mice. Thus, this study sought to further detail if these
chondroprotective effects could be induced by other comparable HS mimetics. In
FIG 5 Prophylactic PG545 treatment reduces HPSE. (i to iii) Muscles and joints were homogenized for
ELISA and/or RNA extracted for qPCR analysis as described previously. The y axis is the ﬁnal calibrated
transcript expression graphed as fold shift, and the x axis designates the treatment groups. (iii)
PBS-homogenized muscle lysates were assayed for use in a commercial sandwich ELISA kit. OD readings
were extrapolated against a set of 7 standards to determine protein concentrations in pg/mg. Values are
expressed as means  SEM from 4 to 17 mice per group. PBS, mock-infected PBS control; PG545, mock
infected and PG545 treated; RRV, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545
treated. HPSE, heparanase.
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agreement with the PPS study, our ﬁndings also show both surface and subsurface
articular irregularities in peak RRVD, which were reduced with PG545 treatment. While
mock-infected PBS control and mock-infected PG545-treated samples stained evenly
for Safranin O (SAFO) at their tibiofemoral articular surfaces, RRV-infected PBS-treated
samples stained unevenly, with variations in the proteoglycan distribution within the
articular topology. Moreover, RRV-infected PBS-treated groups demonstrated cartilage
erosion (Fig. 6Ai, black arrows) at their anterior lateral tibial cartilage regions, exposing
the underlying subchondral bones. Interestingly, there were also higher frequencies of
diffusely spread hypertrophic chondrocytes found along the articular surfaces in these
animals, while only infrequent hypertrophic chondrocytes were seen in control groups.
Curiously, the anterior lateral meniscus in RRV-infected PBS-treated mice was also
observed to be rich in proteoglycan content with high numbers of inﬁltrating ﬁbro-
chondrocytes, which were observed to a lesser extent in the other groups. In contrast,
RRV-infected PG545-treated mice did not experience a loss or weakening of their
proteoglycan staining index. Quantiﬁcation of the joint interface at lateral femur and
lateral articular cartilage showed an overall reduction (P value of 0.05) in cartilage
thickness index in RRV-infected PBS-treated mice compared to that of RRV-infected
PG545-treated mice in the tibial articular compartment (Fig. 6Aii and iii). Moreover, the
systemic concentrations of cartilage oligomeric matrix protein (COMP) and cross-linked
C-telopeptides of type II collagen (CTX-II) (Fig. 6B) in the serum were also signiﬁcantly
higher (P value of 0.01) in the RRV-infected mock-treated group than in the RRV-
infected PG545-treated group.
Prophylactic PG545 treatment protects growth plate thinning associated with
RRV disease. As previously reported in our earlier studies (16), a similar reduction in the
tibial epiphyseal growth plate width in the RRV-infected PBS-treated mice (Fig. 7Ai and
ii) was also observed. Moreover, all three zonal regions of the growth plate in the
RRV-infected PBS-treated mice were also highly reduced (Fig. 7Aii). As expected, this
effect of cartilage atrophy was signiﬁcantly less in RRV-infected PG545-treated mice
(coronal plane, P value of 0.0001; sagittal plane, P value of 0.01). Figure 7Bi and ii
shows that PG545 protects against the RRV-associated growth plate width reduction.
Therapeutic administration of PG545 does not modify the clinical disease in
RRV-infected mice but weakly reduces viral load in target organs. Following
success in prophylactic treatment with PG545 for RRVD in mice, the outcomes of PG545
treatment after RRV exposure at onset of disease and at peak viremia (described in
previous studies as 2 dpi in RRV-infected mice [29, 45]) were examined. Mice were
infected with RRV or mock infected with PBS alone and then treated s.c. with either
PG545 or PBS at 20 mg/kg for the ﬁrst dose at 3 dpi, and thereafter a second dose of
10 mg/kg was given at 7 dpi (Fig. 8Ai). This therapeutic treatment regimen resulted in
no observable difference in clinical disease between the RRV-infected PG545-treated
and RRV-infected PBS-treated groups (Fig. 8Aiii). Interestingly, despite the overall
indifference to disease scores, a signiﬁcant RRVD-induced weight loss (P value of0.05)
was observed in RRV-infected PBS-treated mice compared to weights of RRV-infected
PG545-treated mice at 10 dpi (Fig. 8Aii). Further, therapeutic PG545 treatment still
reduced cellular inﬁltrate accumulation in muscles in RRV-infected PG545-treated mice
(mean count of 1,371.50 141.73) but not RRV-infected PBS-treated mice (mean count
of 2,241.75  476.27) (Fig. 8Bi and ii). Curiously, this reduction in immunocytes was in
direct correlation (P value of 0.05) to the reduced viral load observed in the muscles
of RRV-infected PG545-treated mice (Fig. 8C). Although joints did not show a signiﬁcant
reduction in viral load between the infected PG545-treated and infected PBS-treated
groups, a smaller downward trend was noted in the joints of RRV-infected PG545-
treated mice.
Therapeutic PG545 regimen exerts a modest anti-inﬂammatory effect by re-
ducing the upregulation of MCP-1 and IL-6 in the muscles and HPSE in the joints
of RRVD mice. Following the musculoprotection seen in Fig. 8B and C, a further
downregulation was noted in MCP-1 (P value of 0.01) and IL-6 (P value of 0.05) in
the muscles of RRV-infected PG545-treated mice compared to those in the muscles of
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FIG 6 Prophylactic PG545 treatment protects chondrocytes from RRV-induced cartilage damage and breakdown. (A) Knee joints were
ﬁxed in 4% PFA and then decalciﬁed in 14% EDTA and stained with Safranin O/fast green. (Ai to iii) The width of the articular cartilage
was enumerated from 6 distinct regions of the tibiofemoral cartilage interphase. (Bi and ii) Serum was used to quantify cartilage
breakdown proteins. COMP and CTX-II were used in commercial sandwich ELISA kits. PBS, mock-infected PBS control; PG545, mock
infected and PG545 treated; RRV, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545 treated. Values are expressed
as mean width (m) or mean protein concentration (ng or pg/ml)  SEM for 4 to 16 mice per group. SB, subchondral bone; eGP,
epiphyseal growth plate; ALM, anterior lateral meniscus; PLM, posterior lateral meniscus.
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FIG 7 Prophylactic PG545 treatment protects against RRV-induced growth plate thinning. (Ai and ii) Knee joints were ﬁxed with 4%
PFA, decalciﬁed in 14% EDTA, and stained with either Safranin O/fast green or H&E. (Bi and ii) The width of the growth plate cartilage
was enumerated at 5 distinct points to evaluate overall growth plate thickness. PBS, mock-infected PBS control; PG545, mock infected
and PG545 treated; RRV, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545 treated. Values are expressed as mean
width (m)  SEM for 4 to 16 mice per group. SB, subchondral bone; eGP, epiphyseal growth plate; RZ, resting zone; PZ, proliferation
zone; HZ, hypertrophic zone; CZ, calciﬁed zone.
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RRV-infected PBS-treated mice (Fig. 9). While there was no signiﬁcant difference be-
tween all other soluble host factors across joints and muscles in both RRV-infected
PG545-treated and RRV-infected PBS-treated groups, it is noteworthy that HPSE was still
downregulated (P value of 0.05) in the joints of RRV-infected PG545-treated mice
FIG 8 Therapeutic PG545 treatment does not have any clinical outcome in mice with RRVD at peak disease but maintains an
antiviral effect on tissue-bound virus. (A) In the therapeutic treatment model, 3-week-old C57BL/6 mice were infected s.c. with
104 PFU/50 l PBS or PBS alone on day 0 in the right thorax and also received s.c. injections of PG545 or mock-infected PBS
3 and 7 dpi in the right thorax. Mice were weighed and scored for disease progression as described in Materials and Methods.
(B) Muscles were ﬁxed in 4% PFA and H&E stained, and total cell inﬁltrate counts per section were enumerated. (C) Muscle and
joints were homogenized and RNA was extracted for downstream viral genomic material analysis using nsP3 region-speciﬁc
primers. For data analysis, plasmid copy numbers were extrapolated from RRV T48 standards (n  7). Values are expressed as
means  SEM from 4 to 10 mice per group.
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FIG 9 Therapeutic PG545 treatment reduces upregulation of MCP-1 and IL-6 in muscles and HPSE in joints of RRVD mice. Muscles and joints were
homogenized and RNA extracted to analyze soluble host factor expression via qPCR. The y axis is the ﬁnal calibrated transcript expression,
(Continued on next page)
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compared with RRV-infected PBS-treated mice. A small downward trend of HPSE was
also observed in muscles of RRV-infected PG545-treated mice (Fig. 9). Overall, these
postexposure ﬁndings suggest only partial anti-inﬂammatory and anti-HPSE effects by
PG545 when administered after peak viremia.
DISCUSSION
Certain viruses, including herpes simplex virus (HSV), dengue virus (DENV), respira-
tory syncytial virus (RSV), and alphaviruses such as SINV, utilize cell surface heparan
sulfate proteoglycans (HSPGs) as coreceptors to anchor their viral proteins and subse-
quently infect healthy host cells (21, 26, 31, 32). The precise mode of entry of HS
binding viruses enables HS mimetics to display a favorable antiviral or virucidal activity.
As alternate virus binding HS ligands, HS mimetics can antagonize the viral attachment
proteins’ afﬁnity to HSPG on the cell membrane (21). Recently, the HS mimetics suramin
and PPS have demonstrated favorable disease outcomes when used to treat RRVD
and/or CHIKVD in mice (16, 17). Further, PG545 has also shown high potency as a
virucidal agent against both RSV and HSV-2 particles despite its initial discovery as an
anticancer drug (21, 22, 33). The present study examined if a similar mode of viral
inhibition could be demonstrated for PG545 with RRV, CHIKV, and BFV. Dose-
dependent IC50s were assessed on strains of RRV, CHIKV, and BFV, with PG545 showing
efﬁcacious viral inhibition on all strains tested. Previous viral studies on PG545 reported
that the virucidal activity of PG545 contributes to inhibition of viral attachment to
target cells and neutralization of virus, rendering the virus noninfective (21, 22).
Therefore, binding interactions were assessed by evaluating the afﬁnity and stoichi-
ometry of PG545 binding to whole viral proteins. Results indicated efﬁcient binding
afﬁnity between PG545 and viral protein, as demonstrated by KD values that mostly
ranged from 4 (0.42) M to 0.25 (0.12) M.
We recently reported that HPSE, an endoglycosidase implicated in the pathogenic
remodeling of HS proteoglycans, is upregulated in RRV-infected primary human chon-
drocytes and RRV-infected primary skeletal muscle cells (11). In vivo, we report a similar
elevation of HPSE expression in both joints and muscles of RRV-infected mice. Addi-
tionally, RRV-infected PG545-treated mice also conferred a reduction in HPSE protein
levels in muscles. Some studies report that HPSE remodeling of the ECM can also
negatively affect immunocyte recruitment, activation, and extravasation and migration
to inﬂamed or injured sites (34). Studies show that HPSE has a role in modulating
neutrophils, macrophages, and dendritic cells in an acute inﬂammatory event (35). This
could be due largely to its ability to cleave HS chains, releasing matrix-anchored
cytokines and chemokines, thereby exacerbating the inﬂammatory response. Our
results show that in addition to the reduction in HSPE expression, the presence of
inﬂammatory monocytes and neutrophils (Fig. 2Ci and ii) were also remarkably reduced
in the muscles of the RRV-infected PG545-treated groups. Pronounced immune inﬁl-
trate proliferation and adverse changes to the striated muscle ﬁbers with localized
necrosis to ﬁbers (based on hematoxylin and eosin [H&E]- and phosphotungstic acid
hematoxylin [PTAH]-stained tissue sections) were also observed (Fig. 2Bi and ii), while
the prophylactic administration of PG545 to infected mice substantially restricted
prominent leukocyte recruitment and preserved tissue morphology. A recent study
reported that the upregulation of HPSE in hepatocellular carcinoma causes both tissue
damage and breakdown with ﬁbrosis, similar to the damage often observed in RRVD
musculature at peak disease. The study further reports that inhibiting HPSE with
suramin restored liver integrity (36). This observation suggests that the ability of PG545
to impede HPSE expression allows the maintenance of ECM and thus deters the
extravasation of inﬂammatory cells to potentiate tissue damage. However, whether the
FIG 9 Legend (Continued)
graphed as fold shift, and the x axis designates the treatment groups. PBS, mock-infected PBS control; PG545, mock infected and PG545 treated;
RRV  PBS, RRV infected and PBS treated; RRV  PG545, RRV infected and PG545 treated. Values are expressed as mean mRNA fold change in
expression  SEM for 4 or 5 mice in each group.
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proliﬁc production of HPSE is a host defense reaction to the dysregulation in tissue
homeostasis or a pathogenic action in tandem with proinﬂammatory mediators exac-
erbating disease states remains to be elucidated.
It was found that the expression of soluble host factors IL-6, MCP-1, IFN-, and TNF-
were either signiﬁcantly reduced or followed a downward trend with the RRV-infected
PG545-treated mice, while the extensively reported gene upregulation was observed in
RRV-infected PBS-treated mice. Interestingly, VEGF-A upregulation was also noted in
prophylactic RRV-infected PG545-treated mice, where VEGF-A has been shown to be a
biomarker of PG545 response (33).
Recently it was found that RRVD joint pathology was an element contributing to
viral inﬂammatory arthritis/disease. Studies on arthritis report that HS proteoglycan-
containing collagen damage often occurs within articulating joints during diseased
states (37, 38). Thus, loss of proteoglycans is a fundamental cause of matrix vulnerability
and forms the framework for cartilage erosion in OA patients (37). Consistent with this,
we have previously reported and currently conﬁrm weakened proteoglycan staining on
the articular cartilage lining the joints in addition to cartilage deterioration in RRV-
infected PBS-treated mice, with no visible cartilage erosion in RRV-infected PG545-
treated mice. Moreover, COMP, a tissue-speciﬁc protein bound to type II collagen, and
CTXII, a prognostic marker for cartilage turnover, were both found to be in lower
concentrations in the RRV-infected PG545-treated group than the RRV-infected PBS-
treated group (39). Both COMP and CTX-II have been reported to be byproducts of joint
and/or ECM deterioration and thus can be considered markers to detect the onset of
OA. During damage, COMP and/or CTX-II are initially released into the synovial ﬂuid and
then enter the systemic circulation in the serum (39). Interestingly, mock-infected
PBS-treated mice had an elevation of CTX-II comparable to that of RRV-infected
PBS-treated mice. A study on OA in rabbits reported that the initial high elevation of
CTX-II protein in young rabbits at 224  118 pg/ml, which was also 20-fold higher than
that in adult rabbits, is a result of growth plate activity in young animals which
decreases with age. The growth plate remains active in rabbits until 12 weeks (40).
Similarly, the RRV disease model consists of young mice from 3 weeks of age, which
may pose a challenge to accurately distinguish cartilage or ECM breakdown using
CTX-II as a marker. However, it can still be noted that the PG545 treatment has
signiﬁcant inﬂuence over cartilage and ECM turnover (Fig. 6 and 7). Additionally,
chondroprotection and well-preserved proteoglycan staining of the hyaline structures
of the lateral tibiofemoral interface, as well as the epiphyseal growth plate in RRV-
infected PG545-treated mice, was noted, unlike the case for the RRV-infected PBS-
treated mice. While a reduction in disease progression and hind limb dysfunction in
prophylactic PG545-treated RRV-infected mice was observed, insufﬁcient clinical ben-
eﬁt of PG545 treatment was noted when administered therapeutically at 3 dpi after the
onset of peak viremia at 2 dpi. There were no differences in disease progression
between the RRV-infected PG545-treated group and the RRV-infected mock-treated
group in the therapeutic treatment regimen.
Interestingly, the regulation of VEGF-A remained only moderately elevated between
the RRV-infected PG545-treated and RRV-infected PBS-treated groups. VEGF-A is an
established biomarker of PG545 response. Thus, this observation led to the conclusion
that the anti-heparanase and/or antiviral activity of PG545 only has partial therapeutic
effects on muscles and had no effect once virus had reached peak viremia. This
suggests that the compound can only act efﬁcaciously on RRV at an entry stage, not
once it has undergone several rounds of replication and ampliﬁcation. The effect of this
replication and any subsequent mutations/modiﬁcations to virus may contribute to this
observation and require further studies. Moreover, PG545 was recently reported to be
a potent prophylactic antiviral agent to HSV in animal models, demonstrating effective
virucidal activity by disrupting the envelope proteins of HSV-2 (21). Although the
therapeutic beneﬁt of PG545 remains weak, it should be noted that when treated prior
to viral adsorption in vitro and prophylactically prior to virus inoculation in vivo, PG545
has high antiviral potency against RRV, BFV, and CHIKV infection.
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These results show a potential role of PG545 as an immune-modulating agent with
antiviral and anti-inﬂammatory properties in a time-dependent manner. This study also
provides evidence to support further studies regarding the feasibility of using PG545
prophylaxis to treat arthritogenic alphaviral disease. As PG545 is already in clinical trials,
there is the potential to develop it as a prophylactic agent that could be taken prior to
travel to areas where arthritogenic alphaviruses are endemic. Additionally, it could also
serve as an agent that could be administered to a vulnerable population to curtail
outbreaks. In conclusion, our ﬁndings demonstrate that while prophylactic PG545
treatment only mitigates acute disease, it remains antiviral in both prophylactic and
therapeutic applications in mice with RRVD.
MATERIALS AND METHODS
Viruses and cells. Stocks of the laboratory strain RRV T48 were generated from the full-length T48
cDNA clone (kindly provided by Richard Kuhn, Purdue University). The Asian CHIKV isolate was isolated
in the early 1960s (GenBank accession number FJ457921) (30). The ECSA strain was Reunion Island isolate
LR2006-OPY1 from the outbreak in Reunion Island in 2005 and was generated from an infectious clone
of the primary isolate kindly provided by Andres Merits, University of Tartu, Tartu, Estonia (GenBank
accession number DQ443544.2) (41). Details of BFV 2193 can be found in reference 42. All further
titrations and IC50 values were evaluated by plaque assays of Vero cells. Vero cells were grown in 3% fetal
calf serum (FCS) in Opti-MEM and maintained in 1% FCS in Opti-MEM.
IC50 assay. Plaque assays for IC50 determination were performed as described previously, with some
modiﬁcations (16, 21). Brieﬂy, for IC50 determination of previral adsorption PG545 treatment, serially
diluted virus was incubated with various concentrations of PG545 (42.3 M [100 g/ml], 8.46 M [20
g/ml], 1.69 M [4 g/ml], 0.34 M [0.8 g/ml], and 0.068 M [0.16 g/ml]) for 20 min at room
temperature. Vero cells then were adsorbed with the serially diluted virus samples alone or with virus and
PG545 mixture for 1 h, after which cells were washed and 1% agar overlay was added. For IC50
determination of PG545 treatment response to postviral adsorption, 100 l of various compound
concentrations (as described above) was added prior to wash and 1% agar overlay. Plaque assays were
incubated for 2 days at 37°C and then formaldehyde ﬁxed and stained for 30 min with 1% crystal violet
to visualize plaques.
To extrapolate the IC50s of compounds to the different ﬁeld isolates, a dose-response (semilogarith-
mic) graph was charted. Percentage inhibition was calculated by the formula [1  (number of plaques
test compound/number of plaques control)]  100. Percent inhibition was plotted against the various
PG545 concentrations (in micromolars and micrograms per milliliter) to estimate the IC50s. For plaque
assays, virus titers were denoted as PFU/milligram of tissue or PFU/milliliter for supernatants, where PFU
is characterized as a unit of infectiousness of the virus.
Isothermal calorimetry analysis of alphavirus-PG545 interaction. Isothermal titration calorimetry
experiments were carried out with the nano-ITC low-volume calorimeter (TA Instruments). Both virus and
ligand (PG545) solutions were prepared in PBS. The calorimeter was electrically calibrated according to
the manufacturer’s instructions. Ten million PFU of ECSA CHIKV strain, Asian CHIKV strain, BFV2193, or
RRV T48 was loaded into the calorimeter cell, while the titration syringe was loaded with 8.46 to 15 M
PG545. Titrations were carried out using 20 injections of 2.5 l each, injected at 3- to 4-min intervals at
a constant temperature of 25°C. As a control experiment, PG545 was titrated into the cell with only PBS
buffer. The temperatures of control blanks of PG545 in PBS alone were subtracted from those of the
virus-PG545 interactions, measuring the changes in temperature caused by an injection of PG545 in
diluent (PBS) alone (compound effects) and providing a single value for subtraction. Stirring was
maintained at 150 rpm as suggested by the manufacturer. Analysis was performed using the NanoAna-
lyze program (TA Instruments). KD values were enumerated from two independent experiments and
deﬁned with standard errors of the means (SEM). Calorimetric data were plotted and ﬁtted using the
independent site binding mode.
Compound treatment. PG545 was prepared according to the literature (19). Treatment with PG545
or vehicle alone was given s.c. at 20 mg/kg of body weight in 100 l PBS (vehicle) for the initial preload,
while 10 mg/kg in 50 l PBS was given as the second dose. The dosing schedule and regimen for the
PG545 treatment was determined in accordance with the pharmacokinetic (PK) properties from the
numerous mouse tumor models published (20, 43). Drug delivery design consisted of both prophylactic
and therapeutic intervention, where prophylactic treatment was initiated 1 day prior to the virus
infection and thereafter dosed at 4 dpi, while treatment was initiated after peak viremia in mice at 3 dpi
in therapeutic investigations. The in vitro cellular cytotoxicity of PG545 was evaluated by previous studies
to be from 230 g/ml in HEp-2 cells (22) to 200 g/ml in African green monkey kidney (GMK AH1)
epithelial cells (21); therefore, we set the upper limit of our compound concentration at 100 g/ml.
Animal model. C57BL/6 wild-type mice were purchased from the Animal Resources Centre (Perth,
Australia) and kept in-house until the termination of experiments. All animal experiments were con-
ducted in strict accordance with the Grifﬁth University Animal Ethics guidelines deﬁned by the Animal
Ethics Committee. Twenty-one-day-old C57BL/6 mice were inoculated s.c. with 104 PFU RRV in 50 l of
PBS in the right thorax to initiate RRVD as described previously (16). Mock-infected mice were inoculated
with PBS alone. Mice were weighed and checked daily for disease signs. Early in infection, mice display
mild signs of disease, such as rufﬂed fur with an increase in lethargy and diminished gripping ability,
which progresses to a thorough loss of hind limb activity at peak disease on day 10. As outlined in
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previous studies, the disease in RRV-infected mice encompasses 4 main phases, where 2 dpi is the peak
viremic phase, 5 to 7 dpi the onset of disease phase, 10 dpi the peak disease phase, and 15 dpi the clinical
disease recovery phase (44). Mice were euthanized via CO2 asphyxiation on days 1, 3, 5, 7, and 10
postinfection for all sample analyses.
Histology. At sacriﬁce, intact mouse knee joints were harvested by resection of femur (1 cm above
the patella) and tibia (0.5 cm above the ankle joint), in addition to quadriceps (muscle attached to the
femur), and ﬁxed in 4% paraformaldehyde (PFA) for 1 to 3 days for histological evaluation of overall tissue
alterations, such as tissue and cellular morphologies or cellularity. Bone structures such as the knee joints
were further decalciﬁed in 14% EDTA prior to embedding in parafﬁn blocks. Fixed parafﬁn tissue blocks
were sectioned either in longitudinal (quadriceps), sagittal (knee), or coronal (knee) orientation to 5-m
thickness and stained with hematoxylin and eosin (H&E), phosphotungstic acid hematoxylin (PTAH), or
SAFO/fast green stain. Fast green only stains the surface layer of the articular cartilage and was used to
evaluate cartilage erosion at the articulating surfaces. PTAH was used to conﬁrm muscle necrosis and
collagen breakdown. Stained slides were mounted with DPX coverslips and imaged at 4, 10, or 20
magniﬁcations under an Olympus BX60 microscope. The lateral femoral condyle or lateral tibial plateau
cartilage thickness was measured (at 100 magniﬁcation) at 6 speciﬁed points across the anterior-to-
posterior regions of the cartilage. Further cartilage width was deﬁned as the region of uncalciﬁed
cartilage and calciﬁed cartilage regions; the areas below the tidemark were not included in the
measurement. Epiphyseal widths were quantiﬁed only using the growth plates within the lateral tibia by
an average of 5 different points throughout the axis of the growth plate. Each point of the width
considered the regions from resting chondrocytes to the hypertrophic chondrocytes. All quantitative
measurements were obtained using Cell Sens digital software and are represented as SEM from 4 to
5 mice per group.
Real-time PCR. Tissues were lysed using TissueLyser II (Qiagen) prior to RNA extraction from tissue
homogenates using TRIzol (Life Technologies, Melbourne, Australia) per the manufacturer’s instructions.
Purity and concentration of total RNA was measured using a NanoDrop 1000 spectrophotometer
(Thermo Scientiﬁc, Victoria, Australia). Total RNA (20 ng/l) was reverse transcribed to cDNA using 1 g
RNA template per sample using random nanomers and reverse transcriptase (Sigma-Aldrich, Sydney,
Australia) according to the manufacturer’s instructions. Converted cDNA was diluted to 10 ng/l and
stored at 20°C until further qPCR assay. The qPCRs were performed with a ﬁnal volume of 12.5 l for
every reaction mixture using SsoAdvanced SYBR green supermix. Plates were run using a typical
three-stage melt program conditioned at an initial activation step of 15 min at 95°C, followed by 40
cycles of 15 s at 95°C and 30 s at 55°C, and then a dissociation stage for 30 s at 72°C to ensure the
presence of a single ampliﬁcation peak. qPCR assays were performed on a CFX96 Touch real-time PCR
detection system using either QuantiTect primer assay kits (Qiagen, Hilden, Germany) or primers
purchased from Sigma-Aldrich to detect gene transcripts. Dissociation curves and threshold cycle (CT)
values were acquired using CFX Manager software to verify ampliﬁed amplicons. Relative expression of
the genes of interest was quantitated using the comparative CT method, calculating differences in gene
expression as a relative fold distinction between treatment groups and PBS (mock)-treated calibrator
groups. The CT ratios were normalized to the CT value of the housekeeping gene (HPRT1) to give ΔCT.
Brieﬂy, ΔΔCT  ΔCT (RRV infected)  ΔCT (mock PBS infected), where ΔCT  CT (gene of interest)  CT
(HPRT1). The ﬁnal fold change for each gene was calculated as 2ΔΔCT.
Viral load quantiﬁcation. A standard curve was generated using 7 serially diluted standards of RRV
T48 infectious plasmid DNA. Quantiﬁcation of viral loads was performed using SsoAdvanced universal
probes supermix in half-volume reaction mixtures (12.5 l) to detect nsP3 regions of the viral genomic
material. Reactions were performed using a Bio-Rad CFX96 Touch real-time PCR detection system on
96-well plates as described previously. Cycler conditions were set in 2 parts, an initial PCR activation step
at 95°C for 3 min for 1 cycle and a second step with a cycling protocol of 95°C for 15 s and then 60°C
for 45 s for 45 cycles. A standard curve was derived from the extrapolation of viral copy numbers of
ampliﬁed products from the 7 standards with known plasmid copy numbers.
Sandwich ELISA. The serum COMP (MBS451829; 1:5 dilution; MyBioSource) and CTX-II (MBS760453;
1:10 dilution; MyBioSource) concentrations and the muscle HPSE (MBS453434; 1:100 dilution; MyBio-
Source) level of each group were measured using commercial sandwich ELISA. Brieﬂy, 100 l standard
or sample was added to each well, and the plate was taped and incubated for 120 min or 90 min at 37°C.
The liquid in each well then was decanted, and 100 l of biotinylated detection antibody working
solution was added to each well. The plate was covered and incubated for 1 h at 37°C. Each well then
was washed with wash buffer three times, 100 l of horseradish peroxidase (HRP)-conjugated working
solution was added to each well, and the plate was covered and incubated for 30 min at 37°C. Each well
was washed with wash buffer ﬁve times, 90 l of substrate was added to each well, and the plate was
covered and incubated for 15 to 25 min at 37°C. Fifty microliters of stop solution was added to each well
to stop the reaction when the wells turned a medium shade of blue. The optical density (OD) value of
each well was determined immediately using a microplate reader at a wavelength of 450 nm. The COMP,
CTX-II, and HPSE concentrations were calculated using the standard curve.
Flow cytometry. For ﬂow cytometry, muscles were removed and processed as single-cell suspen-
sions as described elsewhere (16). Brieﬂy, quadriceps were enzymatically digested with 3 mg/ml
collagenase IV and 1 mg/ml DNase I in 100 l RPMI 1640 at 37°C for 1.5 h, resuspended in 3 ml RPMI,
and ﬁltered through 70- and 40-m cell strainers prior to antibody panel staining. Cells were washed,
pelleted, and counted. To determine percentages of speciﬁc leukocyte populations, cells were treated
with Fc block (2.4G2; BD) for 5 min at 4°C and/or labeled with a panel of ﬂuorochrome-conjugated
anti-mouse antibodies, including anti-CD45 antibody (30-F11; eBioscience), anti-CD3-ﬂuorescein
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isothiocyanate (145-2C11; BD), anti-CD19-allophycocyanin (APC) (MB19-1; eBioscience), anti-CD11b-
phycoerythrin (M1/70; BD), and anti-Gr1-APC (RB6-8C5; eBioscience) in various combinations at 4°C for
40 min in the dark. Cells were resuspended in 1,000 l chilled ﬂuorescence-activated cell sorting buffer
(PBS plus 2% fetal calf serum) and were stained with propidium iodide dye (1 g/ml; Sigma-Aldrich). Cells
were counted on a CyAn ADP ﬂow cytometer (Beckman Coulter). Single stained tubes were used as
important control tubes for compensation of spectral overlaps. To ensure analysis was performed on
viable cells only, PI-positive cells were excluded from analysis (Kaluza; Beckman Coulter). All postanalysis
was performed using Kaluza software (Beckman Coulter).
Statistical analysis. One-way analysis of variance (ANOVA) with Tukey’s or Dunnett’s posttest was
used for determining the differences in gene transcription fold change, tibial growth plate width, femoral
condyle and tibial plateau thickness, H&E cell inﬁltrate count, and protein concentrations between
groups. The percent weight gain and viral kinetics in target organs and viremia were assessed using
two-way ANOVA with Bonferroni’s posttest. Mann-Whitney U test was used to evaluate statistical
signiﬁcance for ﬂow cytometry analyses, viral loads, and disease scores. All statistics were performed with
GraphPad Prism 6.0, and P values of 0.05 (*), 0.01 (**), 0.001 (***), and 0.0001 (****) were
considered statistically signiﬁcant.
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